ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 597

Inflammatory Burden in Recent-Onset Axial Spondyloarthritis

Juan Jose Aznar Sánchez1, Raul Veroz Gonzalez1, Adela Gallego Flores1, Tamara Libertad Rodriguez Araya1, Piter José Cossio Jimenez2 and Eugenio Chamizo Carmona1, 1Rheumatology, Hospital de Mérida, Mérida, Spain, 2Hospital de Mérida, Mérida, Spain

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Ankylosing spondylitis (AS), human leukocyte antigens (HLA), Inflammation, magnetic resonance imaging (MRI) and spondylarthritis

  • Tweet
  • Email
  • Print
Session Information

Title: Spondyloarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment I

Session Type: Abstract Submissions (ACR)

Background/Purpose

Patients with Non-Radiographic Axial Spondylarthritis (non-Rx AxSpA) don’t presnt with different clinical manifestations than patients with Ankilosing Spondylitis (AS), although the inflammatory burden measured by ASDAS and CPR is higher in the latter.  Stydies have still yet to discover any difference in inflammatory burden between patients with non-Rx SpA classified by ASAS criteria by the pathway of imaging (active inflammatory lesions in sacroiliac joints detected by MRI) and that classified by the clinical pathway (HLA-B27). The aim of this study is to analyze the clinical characteristics and the inflammatory burden of patients classified of Axial Spondylorarthritis (AxSpA) by ASAS criteria attended in recent-onset Spondyloarthritis Unit (RSpAU).

Methods

We included adult patients younger than 45 years old attended the RSpAU of the General Hospital in Mérida (Spain) between May 2008 and May 2014 with inflammatory low back pain more than 3 months and less than 2 years, asymmetric arthritis and/or mechanical low back pain/arthralgias accompanied by , at least, one of the following: psoriasis, uveitis, inflammatory bowel disease (IBD), entesytis, sacroiliitis on imaging, HLA-B27(+) or familiy history of SpA. Patients with previous diagnosis of SpA were however excluded.

Results

We studied 132 patients, 36 patients fulfilled ASAS criteria for SpA. Of this group, 8 patients fulfilled NY criteria for EA, and 28 were diagnosed with non-Rx SpA. Of the patients with non-Rx SpA, 16 entered through the clinical pathway (HLA-B27) and 12 through the pathway of imaging (MRI of sacroiliac joints with active inflammatory lesions or bone marrow edema). The age at the diagnosis was 29.5 year for both EA and non-Rx SpA. In the group of non-Rx SpA  we found female predominance (16 women/12 men), in particular in the group with MRI positive and HLA-B27 negative (4 women/2 men). The measures of BASDAI and BASFI indexes were higher in the group of non-Rx SpA, but without  stadistically significance. In patients with non-Rx SpA, the medium level of CRP was higher in patients with positive MRI than patients that entered by the clinical pathway, but without sadistically significance.

Conclusion

In the non-Rx SpA there is a female predominance and a lower rate of HLA B27 (+) than in radiological EA. We didn’t find any significant differences in the indexes used to measure the inflammatory burden between both groups. There is a trend to higher inflammatory burden measured by CRP and ASDAS in EA than in non-Rx SpA and in the last group, higher in patients with active inflammatory lesions in sacroiliac joints by MRI.


 

nº

H:M

B27+

%

BASDAI

Media

95%IC

ASDAS

Media

95%IC

BASFI

Media

95%IC

EGP

Media

95%IC

PCR (mg/L)

Media

95%IC

TOTAL

36

               0,80

83,33

4,95

(4.26,5.64)

2,83

(2.46,3.20)

2,81

(1.97,3.65)

6,11

(5.2,7.02)

9,02

(3.61,14.43)

AS (NY)

8

1,6

100

4,25

(2.49,6.01)

2,95

(1.72,4.18)

2,425

(0.44,4.40)

5,75

(3.25,8.25)

21,01

(0,43.32)

non-Rx AxSpA

28

0,75

78,6

5,18

(4.40,5,96)

2,8

(2.43,3.31)

2,92

(1.95,3.89)

6,21

(5.21,7.21)

5,61

(2.31,8.91)

HLAB27

16

0,77

100

5,01

(3.86,6.16)

2,72

(2.21,3.23)

2,75

(1.47,4.03)

6,25

(4.86,7.64)

4,87

(0.51,9.23)

RMN

12

0,71

50

5,42

(4.3,6.54)

2,91

(2.3,3.52)

3,14

(1.48,5.80)

6,17

(4.53,7.81)

6,61

(1.12, 12.20)


Disclosure:

J. J. Aznar Sánchez,
None;

R. Veroz Gonzalez,
None;

A. Gallego Flores,
None;

T. L. Rodriguez Araya,
None;

P. J. Cossio Jimenez,
None;

E. Chamizo Carmona,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/inflammatory-burden-in-recent-onset-axial-spondyloarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology